Ambulero develops regenerative cell and gene therapies targeting vascular disease, utilizing engineered stromal cells that express E-selectin and gene therapy vectors to promote tissue repair. Their approach aims to address the lack of effective treatments for vascular ischemia, particularly in young patients, potentially reducing the need for limb amputation.
Funding
$5.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Vascular diseases, particularly vascular ischemia, often lack effective treatments, especially in young patients. Current standards of care may be insufficient, potentially leading to limb amputation in severe cases.
Solution
Ambulero is developing regenerative cell and gene therapies to address vascular disease by promoting tissue repair. Their cell therapy program utilizes engineered stromal cells, referred to as "supercharged MSCs," that express E-selectin to enhance tissue regeneration. The gene therapy program employs established gene therapy vectors to directly deliver the E-selectin molecule to injured tissues. This dual approach aims to provide a novel method for healing tissues damaged by vascular disease, offering new hope for patients.
Target Audience
The primary target audience includes young patients suffering from vascular ischemia and other vascular diseases, as well as healthcare providers seeking advanced treatment options.
Features
- Engineered stromal cells ("Supercharged MSCs") expressing E-selectin to promote tissue repair
- AAV gene therapy vectors for direct delivery of E-selectin to injured tissues
- Pipeline of candidate regenerative products targeting vascular disease